|
| [January 07, 2013] |
 |
Research and Markets: Hemorrhagic Shock Global Clinical Trials Review, H2, 2012
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/wl8clr/hemorrhagic_shock)
has announced the addition of GlobalData's new report "Hemorrhagic Shock
Global Clinical Trials Review, H2, 2012" to their offering.
Hemorrhagic Shock Global Clinical Trials Review, H2, 2012" provides data
on the Hemorrhagic Shock clinical trial scenario. This report provides
elemental information and data relating to the clinical trials on
Hemorrhagic Shock. It includes an overview of the trial numbers and
their recruitment status as per the site of trial conduction across the
globe. The databook offers apreliminary coverage of disease clinical
trials by their phase, trial status, prominence of the sponsors and also
provides briefing pertaining to the number of trials for the key drugs
for treating Hemorrhagic Shock.
Scope
- Data on the number of clinical trials conducted in North America,
South and Central America, Europe, Middle-East and Africa and
Asia-pacific and top five national contributions in each, along with the
clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status,
subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed
manner
- Abridged view of the performance of the trials in terms of their
status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes /
Hospitals or Companies
For more information visit http://www.researchandmarkets.com/research/wl8clr/hemorrhagic_shock
Source (News - Alert): GlobalData

[ Back To Technology News's Homepage ]
|